India's pharma, healthcare deal volumes rise 23% in Q3 2026: Report
Indian markets moved higher in a quarterly results development.
· Business Standard Mkts
India's pharma and healthcare sector recorded 87 deals worth $4.3 billion in Q3 2026, as private equity activity surged and public market fundraising gained momentum.
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Because the driver here is macro rather than company-specific, the read-through is to index-level positioning rather than to any single name — correlations tend to rise when the whole market faces the same signal.
Market context
- A market-wide development: it reaches beyond any single stock.
- Sectors in the story: Pharma & Healthcare.
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Max Healthcare Q2 PAT rises 10% to ₹448 cr on higher bed occupancy
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell
Rupee rises 4 paise to 95.03 against US dollar in early trade